Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, New South Wales, Australia; Westmead Clinical School, The University of Sydney, Sydney, New South Wales, Australia; Department of Gastroenterology and Hepatology, Sydney Adventist Hospital, Sydney, New South Wales, Australia.
Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, New South Wales, Australia; Westmead Clinical School, The University of Sydney, Sydney, New South Wales, Australia.
Gastrointest Endosc. 2023 Jun;97(6):1100-1108. doi: 10.1016/j.gie.2023.01.040. Epub 2023 Jan 28.
Large (≥15 mm) duodenal adenomas (DAs) are premalignant and require removal. Existing endoscopic resection techniques are compromised by serious adverse events (SAEs), most notably postprocedural bleeding (PPB) and perforation. To ameliorate these problems, we sought to evaluate the novel technique of cold snare EMR (CS-EMR) against the emerging standard of conventional EMR with thermal ablation of the postresection margin (EMR-T) for the safe and effective removal of DAs.
Consecutive patients were enrolled in a single tertiary center for CS-EMR and prospectively analyzed against a previously reported cohort of EMR-T from the same center. The primary outcome was rate of SAEs. Secondary outcomes were residual or recurrent adenoma at first surveillance endoscopy (SE1) at 6 months and technical success per lesion.
Between October 2019 and July 2022, a total of 50 DAs ≥15 mm were removed via CS-EMR (median size, 30 mm [interquartile range (IQR), 19-40 mm]; mean ± standard deviation [SD] patient age, 70 ± 9.2 years) compared with 54 DAs via EMR-T (median size, 30 mm [IQR, 19-40 mm]; mean patient age, 68 ± 12.2 years). CS-EMR had a significantly lower rate of intraprocedural bleeding (2.0% vs 37%, P < .001) and PPB (4.0% vs 16.7%, P = .036). Two cases (4.0%) of immediate perforation occurred in CS-EMR; these were recognized immediately and closed with clips without sequelae. Total SAEs (16.0% vs 16.7%, P = 1) and technical success (100% vs 100%, P = 1) were identical. Recurrence at SE1 was significantly higher with CS-EMR (24.4% vs 2.3%, P = .002).
CS-EMR reduces intraprocedural bleeding and PPB. However, it may increase the risk of immediate perforation and is associated with a significantly higher rate of recurrence at SE1. Further technical refinements are required to optimize endoscopic resection techniques for DAs. (Clinical trial registration number: NCT02306603.).
大(≥15mm)十二指肠腺瘤(DAs)是癌前病变,需要切除。现有的内镜切除技术存在严重不良事件(SAEs),最显著的是术后出血(PPB)和穿孔。为了改善这些问题,我们试图评估冷圈套内镜下黏膜切除术(CS-EMR)与新兴的标准热消融切除术后边缘(EMR-T)治疗大 DAs 的安全性和有效性。
连续患者在一家三级中心接受 CS-EMR,并与来自同一中心的之前报道的 EMR-T 队列进行前瞻性分析。主要结局是 SAE 发生率。次要结局是 6 个月时首次内镜监测(SE1)时残留或复发性腺瘤,以及每个病变的技术成功率。
2019 年 10 月至 2022 年 7 月,通过 CS-EMR 切除了 50 个≥15mm 的 DAs(中位大小 30mm[四分位距(IQR),19-40mm];平均年龄±标准差[SD]70±9.2 岁),与 54 个通过 EMR-T 切除的 DAs(中位大小 30mm[IQR,19-40mm];平均年龄 68±12.2 岁)相比。CS-EMR 术中出血(2.0% vs 37%,P<.001)和 PPB(4.0% vs 16.7%,P=.036)的发生率显著降低。CS-EMR 中立即穿孔的病例有 2 例(4.0%);这些穿孔立即被发现并夹闭,没有后遗症。总 SAE(16.0% vs 16.7%,P=1)和技术成功率(100% vs 100%,P=1)相同。SE1 时的复发率 CS-EMR 显著更高(24.4% vs 2.3%,P=.002)。
CS-EMR 可减少术中出血和 PPB。然而,它可能会增加立即穿孔的风险,并与 SE1 时显著更高的复发率相关。需要进一步的技术改进来优化大 DAs 的内镜切除术。(临床试验注册号:NCT02306603.)。